At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 595 enrolled
Drug / intervention
Apremilast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Apremilast and Placebo for Psoriasis. Completed, enrolled 595 participants across 64 sites in 2 countries.
Detailed Summary
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis. Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartMar 2019
Primary CompletionMar 2020
Study CompletionJul 2020
TodayJul 2026
First PostedOct 26, 2018
Enrollment StartMar 11, 2019
Primary CompletionMar 6, 2020
Study CompletionJul 24, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 7.7 years ago
Interventions
Apremilastdrug
Apremilast, oral, twice daily
Placeboother
Placebo, oral, twice daily